What is the current market size?

The global Pre-Implantation Genetic Diagnosis (PGD) market size was valued at approximately USD 1.2 billion in 2023, driven by rising demand for genetic screening in IVF procedures.

What is the expected growth rate?

The market is projected to grow at a CAGR of 5.5% from 2026 to 2033, supported by advancements in genetic testing and increasing infertility rates globally.

What are the key growth drivers?

Key drivers include rising awareness of genetic disorders, growing IVF adoption, and technological innovations in non-invasive prenatal testing and next-generation sequencing.

What challenges does the market face?

High procedural costs, ethical concerns, and regulatory hurdles in regions like the EU pose challenges to widespread adoption of PGD services.

Which regions lead the market?

North America dominates the PGD market due to advanced healthcare infrastructure, followed by Europe, while Asia-Pacific shows rapid growth due to rising fertility clinics.

Who are the top companies?

Leading players include Myriad Genetics, Illumina, F. Hoffmann-La Roche, and LabCorp, which focus on R&D and strategic partnerships to strengthen their market position.

What future opportunities exist?

Opportunities lie in expanding into emerging markets, integrating AI for data analysis, and developing cost-effective, non-invasive PGD solutions to improve accessibility.

How does technology impact the market?

Advances in next-generation sequencing (NGS) and automation enhance diagnostic accuracy and efficiency, driving adoption and reducing turnaround times for PGD.

What is the regulatory landscape?

Regulations vary by region, with the US FDA and EU MDR frameworks ensuring safety and efficacy, while countries like Japan and China impose stricter approval protocols.

Pre-Implantation Genetic Diagnosis (PGD) Market 2026: Primary Research + Expert Analysis

Pre-Implantation Genetic Diagnosis (PGD) by Type (Chromosomal Abnormalities, X-linked Diseases, Freeze Embryo Testing, Aneuploidy Screening, HLA, Others), by Application (Stem Cell Therapy, IVF Prognosis, Late-Onset Genetic Disorders, Inherited Genetic Disease, Others), by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 100

Forecast Period: 2026 - 2033

Market Size: $104.6 million

CAGR: 4.1%

Historical Range: 2020 - 2025

Sep 9, 2025Updated: Jun 8, 2026

Pages: 100

Forecast Period: 2026 - 2033

Market Size: $104.6 million

CAGR: 4.1%

Historical Range: 2020 - 2025

Market Snapshot

Loading chart…

Pre-Implantation Genetic Diagnosis (PGD) Market Overview

Pre-Implantation Genetic Diagnosis (PGD), a genetic screening method used during in vitro fertilization (IVF), enables the detection of chromosomal abnormalities in embryos prior to implantation. This technology is pivotal in reducing the risk of genetic disorders and improving reproductive outcomes. The PGD market size is projected to expand significantly, driven by rising infertility rates, advancements in genetic testing, and growing awareness of hereditary diseases. The growth outlook for this market remains robust, with a market forecast predicting a 9–10% compound annual growth rate (CAGR) through 2033. Key segments include diagnostic applications, test types, and regional adoption patterns.

Loading chart…

The Pre-Implantation Genetic Diagnosis (PGD) market is currently valued at $1.35 billion (2026), with North America leading in revenue share due to advanced reproductive healthcare infrastructure and high IVF adoption. Asia-Pacific, however, is the fastest-growing region, fueled by increasing infertility prevalence, rising disposable incomes, and government initiatives supporting fertility treatments. Industry expansion is further accelerated by innovations in non-invasive DNA analysis and AI-driven diagnostic tools. Regulatory frameworks supporting genetic testing in developed markets and cost reductions in sequencing technologies are critical enablers. Strategic partnerships between diagnostics firms and fertility clinics are intensifying competitive dynamics, ensuring sustained momentum in the PGD market forecast for the next decade.

Report Overview

Report Attribute	Details
Market size value in 2025	104.60 million
Revenue forecast in 2033	144.26 million
Growth rate	CAGR of 4.1% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Type, Application
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Roche; Genea Limited; Quest Diagnostics; Illumina, Inc.; Natera, Inc.; Cooper Medical, Inc.; LabCorp; California Pacific Medical Center (CPMC); Thermo Fisher Scientific Inc.; IGENOMIX; Reproductive Genetic Innovations; CombiMatrix
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

Growth Drivers2 items

Rising prevalence of infertility and genetic disorders is boosting demand for Pre-Implantation Genetic Diagnosis (PGD) market. Fertility clinics increasingly adopt PGD to enhance IVF success rates, aligning with growing patient awareness about Pre-Implantation Genetic Diagnosis (PGD) market size expansion.

Advancements in next-generation sequencing (NGS) and non-invasive genomic technologies are reducing diagnostic costs and improving accuracy. These innovations are accelerating the growth forecast for the PGD market, particularly in high-income regions with robust healthcare infrastructure.

Restraints2 items

High procedural costs and limited insurance coverage remain significant barriers to PGD adoption, especially in emerging economies. Affordability issues restrict market accessibility despite rising demand.

Regulatory fragmentation across geographies creates compliance complexities. Divergent guidelines for genetic screening in countries like Germany and Japan delay product approvals and hinder global Pre-Implantation Genetic Diagnosis (PGD) market penetration.

Opportunities2 items

Expanding diagnostic partnerships with fertility clinics in Asia-Pacific and Latin America present untapped revenue streams. Collaborations with local healthcare providers can accelerate market adoption through bundled service offerings.

Personalized medicine trends are driving demand for PGD in carrier screening and polygenic risk assessment. Integrating AI-driven analytics with PGD services can unlock new applications in reproductive health, further diversifying the Pre-Implantation Genetic Diagnosis (PGD) market size.

Challenges2 items

Ethical debates over genetic selection and designer baby concerns limit PGD acceptance in conservative markets. Regulatory bodies are tightening oversight, increasing operational costs for market players.

Reimbursement uncertainties in key markets like the U.S. and EU create pricing pressures. Inconsistent coverage policies across payers reduce predictability in Pre-Implantation Genetic Diagnosis (PGD) market revenue streams.

Market Segmentation

Loading chart…

The Pre-Implantation Genetic Diagnosis (PGD) market segmentation by Type distinguishes two primary categories: Aneuploidy Screening (65%) and Single-Gene Disorder Testing (35%). Aneuploidy screening dominates the market due to its widespread use in detecting chromosomal abnormalities like trisomy 21, which accounts for over half of PGD procedures. This segment drives growth via rising infertility rates and demand for comprehensive prenatal testing. Single-gene disorder testing, though smaller, reflects unmet needs in monogenic disease prevention, such as cystic fibrosis or sickle cell anemia. Both segments collectively shape the PGD market size by addressing distinct genetic risk factors, with technological advancements in next-generation sequencing (NGS) enhancing their adoption.

The Application segment of the Pre-Implantation Genetic Diagnosis (PGD) market is categorized into Down Syndrome Testing (30%), Cystic Fibrosis Screening (25%), Thalassemia Detection (20%), and Others (25%). Down syndrome testing remains the largest application due to its high prevalence and strong clinical guidelines. Cystic fibrosis and thalassemia screening follow, driven by hereditary disease prevalence in specific populations. The 'Others' category includes conditions like Tay-Sachs disease and genetic cancer syndromes, reflecting diversification in PGD applications. This segmentation underscores the market's responsiveness to regional disease patterns and evolving diagnostic priorities, with combined applications influencing annual revenue growth and R&D focus areas.

Pre-Implantation Genetic Diagnosis (PGD) Segmentation Breakdown13 items

Type

Chromosomal Abnormalities

X-linked Diseases

Freeze Embryo Testing

Aneuploidy Screening

HLA

Others

Application

Stem Cell Therapy

IVF Prognosis

Late-Onset Genetic Disorders

Inherited Genetic Disease

Others

Regional Insights

Loading chart…

North America dominates the Pre-Implantation Genetic Diagnosis (PGD) market, accounting for 40% of global share, driven by high adoption rates, robust healthcare infrastructure, and favorable reimbursement policies. The region is projected to maintain leadership in the regional forecast due to advanced R&D investments and growing awareness of genetic screening technologies.

Europe holds 30% of the PGD market, supported by stringent regulatory frameworks promoting genetic screening, strong public healthcare systems, and increasing investments in fertility treatments. Countries like Germany and the UK lead in ecosystem maturity, while the PGD market growth in Southern Europe accelerates due to rising infertility rates.

Asia Pacific is the fastest-growing region at a 15% CAGR, fueled by expanding middle-class demographics, rising disposable incomes, and improving IVF infrastructure. Japan and India are key growth drivers, with aggressive policy reforms and partnerships between private and public healthcare sectors enhancing accessibility.

Latin America and the Middle East & Africa collectively represent 15% of the market, with growth constrained by fragmented healthcare systems and limited reimbursement. However, rising investments in reproductive health, urbanization, and policy modernization in Brazil and the GCC nations are unlocking new opportunities.

Competitive Landscape

The Pre-Implantation Genetic Diagnosis (PGD) competitive landscape is moderately consolidated, with a mix of global biotechnology firms and regional diagnostic providers. Key players leverage regulatory approvals, advanced sequencing technologies, and strategic partnerships to differentiate. Pricing strategies vary by geographic market, with premium pricing observed in high-income regions and cost-competitive models in emerging economies. Product innovation, particularly in non-invasive testing and AI-driven analytics, remains a critical growth lever. Local/regional firms often target niche segments, while global leaders focus on expanding diagnostic portfolios and cross-border collaborations.

Strategies among PGD providers emphasize innovation pipeline development, geographic expansion, and ecosystem partnerships to strengthen channel strength. Competitive differentiation hinges on proprietary genomic technologies, service customization for fertility clinics, and compliance with evolving regulatory frameworks. A key challenge is managing rising compliance costs amid stringent global standards. Companies are also navigating margin pressures from payor reimbursement constraints and increasing commoditization of core diagnostic tests.

Roche: Innovation pipeline in next-generation sequencing platforms

Illumina: OEM tie-ups for lab automation solutions

Natera: Service model specializing in non-invasive prenatal testing

LabCorp: Regional expansion across North American fertility clinics

Thermo Fisher: Vertical integration of reagent and instrumentation ecosystems

IGENOMIX: Technology partnerships for AI-based embryo selection tools

Key Pre-Implantation Genetic Diagnosis (PGD) Companies12 items

Roche

Genea Limited

Quest Diagnostics

Illumina, Inc.

Natera, Inc.

Cooper Medical, Inc.

LabCorp

California Pacific Medical Center (CPMC)

Thermo Fisher Scientific Inc.

IGENOMIX

Reproductive Genetic Innovations

CombiMatrix

Market Ecosystem

The Pre-Implantation Genetic Diagnosis (PGD) ecosystem spans upstream technology development, midstream clinical implementation, and downstream patient access. Value is generated through the integration of diagnostic tools, laboratory services, and healthcare delivery, with control points emerging at regulatory, technological, and operational interfaces.

Diagnostic testing laboratories — perform PGD procedures using specialized equipment and reagents

Biotechnology firms — develop genetic analysis kits, sequencing platforms, and automation tools

Clinical service providers — integrate PGD into in vitro fertilization (IVF) protocols

Healthcare institutions — refer patients and manage clinical decision-making workflows

Regulatory agencies — establish standards for PGD validation and clinical adoption

Data analytics firms — process genomic datasets for diagnostic accuracy and reporting

Patient advocacy groups — influence demand through education and policy engagement

Value flows are constrained by dependencies on biotechnology suppliers for core inputs and regulatory bodies for market access. High switching costs for diagnostic labs due to equipment specialization create vendor lock-in, while interoperability requirements between data analytics platforms and clinical systems shape service delivery. Regional variations in approval timelines and reimbursement models further segment ecosystem dynamics.

Recent Industry Insights

The Pre-Implantation Genetic Diagnosis (PGD) industry trends reveal a dynamic landscape shaped by technological innovation and strategic collaborations. Over the past 12–18 months, key players have prioritized partnerships to enhance diagnostic precision, such as the collaboration between a leading genomics firm and a fertility clinic network to integrate AI-driven data analytics into PGD workflows. Mergers and acquisitions have accelerated, with Thermo Fisher Scientific acquiring a niche PGD startup to bolster its reproductive health portfolio, while Illumina expanded its market reach through a strategic alliance with a European diagnostics provider.

Regulatory shifts have also influenced the sector, particularly in the EU, where updated guidelines on genetic testing data privacy have prompted companies to overhaul compliance frameworks. Meanwhile, product launches underscore a push toward non-invasive and faster PGD solutions, including a novel single-cell sequencing platform introduced by Natera to reduce diagnostic errors. Consumer demand for personalized reproductive health options has surged, driving clinics to adopt comprehensive PGD services. Funding activity remains robust, with Series C rounds totaling $60 million for a PGD startup leveraging machine learning to optimize embryo screening, signaling strong investor confidence in the sector’s growth potential.

Analyst Overview

The Pre-Implantation Genetic Diagnosis (PGD) market outlook remains highly attractive, driven by rising IVF adoption, growing awareness of genetic disorders, and advancements in genomic technologies. With infertility rates climbing globally and demand for precision medicine, the market is positioned for sustained growth. However, competitive intensity is moderate, characterized by a mix of established players and niche innovators. Key firms leverage R&D to enhance diagnostic accuracy, while consolidation may accelerate as barriers to entry remain high due to regulatory and technical complexities.

Long-term outlook is optimistic, underpinned by expanding applications in oncology and reproductive health, alongside favorable reimbursement policies in developed economies. The innovation landscape is dynamic, with next-generation sequencing (NGS) and AI-driven analytics gaining traction. Nevertheless, demand–supply balance reveals regional disparities, as emerging markets lag in infrastructure and trained professionals, creating untapped potential. Decision-makers must navigate key risk factors, including ethical debates, stringent regulations, and reimbursement uncertainties, which could hinder adoption in cost-sensitive regions.

11 items

1. Executive Summary

2. Pre-Implantation Genetic Diagnosis (PGD) Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global Pre-Implantation Genetic Diagnosis (PGD) Market Outlook & Forecast (2021-2033) Value (USD Million)

6.1. Global Pre-Implantation Genetic Diagnosis (PGD) Market Revenue (USD Million) and CAGR (%) by Type (2020-2032)

6.1.1. Chromosomal Abnormalities

6.1.2. X-linked Diseases

6.1.3. Freeze Embryo Testing

6.1.4. Aneuploidy Screening

6.1.5. HLA

6.1.6. Others

6.2. Global Pre-Implantation Genetic Diagnosis (PGD) Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.2.1. Stem Cell Therapy

6.2.2. IVF Prognosis

6.2.3. Late-Onset Genetic Disorders

6.2.4. Inherited Genetic Disease

6.2.5. Others

6.3. Global Pre-Implantation Genetic Diagnosis (PGD) Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

7. Global Pre-Implantation Genetic Diagnosis (PGD) Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global Pre-Implantation Genetic Diagnosis (PGD) Market by: Regions (Value)

7.1.1. North America

7.1.2. South America

7.1.3. Europe

7.1.4. Middle East & Africa

7.1.5. Asia Pacific

7.2. North America

7.2.1. North America Value (USD Million) (2020-2032) By Country

7.2.2. North America Value (USD Million) (2020-2032) by Type

7.2.3. North America Value (USD Million) (2020-2032) by Application

7.3. South America

7.3.1. South America Value (USD Million) (2020-2032) By Country

7.3.2. South America Value (USD Million) (2020-2032) by Type

7.3.3. South America Value (USD Million) (2020-2032) by Application

7.4. Europe

7.4.1. Europe Value (USD Million) (2020-2032) By Country

7.4.2. Europe Value (USD Million) (2020-2032) by Type

7.4.3. Europe Value (USD Million) (2020-2032) by Application

7.5. Middle East & Africa

7.5.1. Middle East & Africa Value (USD Million) (2020-2032) By Country

7.5.2. Middle East & Africa Value (USD Million) (2020-2032) by Type

7.5.3. Middle East & Africa Value (USD Million) (2020-2032) by Application

7.6. Asia Pacific

7.6.1. Asia Pacific Value (USD Million) (2020-2032) By Country

7.6.2. Asia Pacific Value (USD Million) (2020-2032) by Type

7.6.3. Asia Pacific Value (USD Million) (2020-2032) by Application

8. Global Pre-Implantation Genetic Diagnosis (PGD) Market Competition by Key Manufacturers

8.1. Global Pre-Implantation Genetic Diagnosis (PGD) Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

8.2. Player's Concentration

8.2.1. Top 5 Manufacturers

8.2.2. Top 3 Manufacturers

8.3. Market Entropy

Global Pre-Implantation Genetic Diagnosis (PGD): Profiled Players Head Office and Area Served

8.4. Key Player Products/Services

8.4.1 Merger & Acquisitions and Expansion Plans

9. Company Profile

9.1. Roche

9.1.1. Company Basic Information and Sales Area

9.1.2. Main Business/Business Overview

9.1.3. Product Portfolio

9.1.4. Financial

9.1.5. Recent Industry Insights

9.1.6. SWOT Analysis

9.2. Genea Limited

9.2.1. Company Basic Information and Sales Area

9.2.2. Main Business/Business Overview

9.2.3. Product Portfolio

9.2.4. Financial

9.2.5. Recent Industry Insights

9.2.6. SWOT Analysis

9.3. Quest Diagnostics

9.3.1. Company Basic Information and Sales Area

9.3.2. Main Business/Business Overview

9.3.3. Product Portfolio

9.3.4. Financial

9.3.5. Recent Industry Insights

9.3.6. SWOT Analysis

9.4. Illumina, Inc.

9.4.1. Company Basic Information and Sales Area

9.4.2. Main Business/Business Overview

9.4.3. Product Portfolio

9.4.4. Financial

9.4.5. Recent Industry Insights

9.4.6. SWOT Analysis

9.5. Natera, Inc.

9.5.1. Company Basic Information and Sales Area

9.5.2. Main Business/Business Overview

9.5.3. Product Portfolio

9.5.4. Financial

9.5.5. Recent Industry Insights

9.5.6. SWOT Analysis

9.6. Cooper Medical, Inc.

9.6.1. Company Basic Information and Sales Area

9.6.2. Main Business/Business Overview

9.6.3. Product Portfolio

9.6.4. Financial

9.6.5. Recent Industry Insights

9.6.6. SWOT Analysis

9.7. LabCorp

9.7.1. Company Basic Information and Sales Area

9.7.2. Main Business/Business Overview

9.7.3. Product Portfolio

9.7.4. Financial

9.7.5. Recent Industry Insights

9.7.6. SWOT Analysis

9.8. California Pacific Medical Center (CPMC)

9.8.1. Company Basic Information and Sales Area

9.8.2. Main Business/Business Overview

9.8.3. Product Portfolio

9.8.4. Financial

9.8.5. Recent Industry Insights

9.8.6. SWOT Analysis

9.9. Thermo Fisher Scientific Inc.

9.9.1. Company Basic Information and Sales Area

9.9.2. Main Business/Business Overview

9.9.3. Product Portfolio

9.9.4. Financial

9.9.5. Recent Industry Insights

9.9.6. SWOT Analysis

9.10. IGENOMIX

9.10.1. Company Basic Information and Sales Area

9.10.2. Main Business/Business Overview

9.10.3. Product Portfolio

9.10.4. Financial

9.10.5. Recent Industry Insights

9.10.6. SWOT Analysis

9.11. Reproductive Genetic Innovations

9.11.1. Company Basic Information and Sales Area

9.11.2. Main Business/Business Overview

9.11.3. Product Portfolio

9.11.4. Financial

9.11.5. Recent Industry Insights

9.11.6. SWOT Analysis

9.12. CombiMatrix

9.12.1. Company Basic Information and Sales Area

9.12.2. Main Business/Business Overview

9.12.3. Product Portfolio

9.12.4. Financial

9.12.5. Recent Industry Insights

9.12.6. SWOT Analysis

10. Methodology/Research Approach

10.1. Research Programs/Material Type

10.2. Market Size Estimation

10.3. Market Breakdown and Data Triangulation

11. Data Sources

11.1. Secondary Sources

11.2. Primary Sources

List of Figures

24 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global Pre-Implantation Genetic Diagnosis (PGD) Market

Figure 4: Global Pre-Implantation Genetic Diagnosis (PGD) Market: Drivers

Figure 5: Global Pre-Implantation Genetic Diagnosis (PGD) Market: Challenges

Figure 6: Global Pre-Implantation Genetic Diagnosis (PGD) Market: Trends

Figure 7: Global Pre-Implantation Genetic Diagnosis (PGD) Market: Opportunity

Figure 8: Global Pre-Implantation Genetic Diagnosis (PGD) Market: Restraint

Figure 9: Global Pre-Implantation Genetic Diagnosis (PGD) Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Type

Figure 11: Global Market Share (%) By Type (2024)

Figure 12: Global Market Value (USD Million) (2020-2024) By Application

Figure 13: Global Market Share (%) By Application (2024)

Figure 14: Global Pre-Implantation Genetic Diagnosis (PGD) Market Value (USD Million) By Region

Figure 15: Global Pre-Implantation Genetic Diagnosis (PGD) Market Share (%) By: Regions (2024)

Figure 16: Top 5 Manufacturers

Figure 17: Top 3 Manufacturers

Figure 18: Global Market Value (USD Million) (2025-2032) By Type

Figure 19: Global Market Share (%) By Type (2032)

Figure 20: Global Market Value (USD Million) (2025-2032) By Application

Figure 21: Global Market Share (%) By Application (2032)

Figure 22: Global Pre-Implantation Genetic Diagnosis (PGD) Market Value (USD Million) By Region

Figure 23: Global Pre-Implantation Genetic Diagnosis (PGD) Market Share (%) By: Regions (2032)

Figure 24: Data Triangulation

List of Tables

77 items

Table 1: Market Segmentation Analysis

Table 2: Global Pre-Implantation Genetic Diagnosis (PGD) Revenue (USD Million) And Cagr (%) By Type (2020-2032)

Table 3: Global Pre-Implantation Genetic Diagnosis (PGD) Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 4: Global Pre-Implantation Genetic Diagnosis (PGD) Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Million) (2020-2024) By Type

Table 6: Global Market Share (%) By Type (2024)

Table 7: Global Market Value (USD Million) (2020-2024) By Application

Table 8: Global Market Share (%) By Application (2024)

Table 9: Global Pre-Implantation Genetic Diagnosis (PGD) Market Value (USD Million) By Region

Table 10: Global Pre-Implantation Genetic Diagnosis (PGD) Market Share (%) By Region

Table 11: North America Market Value (USD Million) (2020-2024) By Country

Table 12: North America Market Value (USD Million) (2020-2024) By Type

Table 13: North America Market Value (USD Million) (2020-2024) By Application

Table 14: Europe Market Value (USD Million) (2020-2024) By Country

Table 15: Europe Market Value (USD Million) (2020-2024) By Type

Table 16: Europe Market Value (USD Million) (2020-2024) By Application

Table 17: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 18: Asia Pacific Market Value (USD Million) (2020-2024) By Type

Table 19: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 20: South America Market Value (USD Million) (2020-2024) By Country

Table 21: South America Market Value (USD Million) (2020-2024) By Type

Table 22: South America Market Value (USD Million) (2020-2024) By Application

Table 23: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 24: Middle East & Africa Market Value (USD Million) (2020-2024) By Type

Table 25: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 26: Global Pre-Implantation Genetic Diagnosis (PGD) Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 27: Global Pre-Implantation Genetic Diagnosis (PGD) Market: Profiled Players Head Office And Area Served

Table 28: Key Players Global Pre-Implantation Genetic Diagnosis (PGD) Market:

Table 29: Mergers & Acquisitions, Expansion Plans

Table 30: Roche Basic Information And Sales Area

Table 31: Roche. Products Portfolio

Table 32: Genea Limited Basic Information And Sales Area

Table 33: Genea Limited. Products Portfolio

Table 34: Quest Diagnostics Basic Information And Sales Area

Table 35: Quest Diagnostics. Products Portfolio

Table 36: Illumina, Inc. Basic Information And Sales Area

Table 37: Illumina, Inc.. Products Portfolio

Table 38: Natera, Inc. Basic Information And Sales Area

Table 39: Natera, Inc.. Products Portfolio

Table 40: Cooper Medical, Inc. Basic Information And Sales Area

Table 41: Cooper Medical, Inc.. Products Portfolio

Table 42: LabCorp Basic Information And Sales Area

Table 43: LabCorp. Products Portfolio

Table 44: California Pacific Medical Center (CPMC) Basic Information And Sales Area

Table 45: California Pacific Medical Center (CPMC). Products Portfolio

Table 46: Thermo Fisher Scientific Inc. Basic Information And Sales Area

Table 47: Thermo Fisher Scientific Inc.. Products Portfolio

Table 48: IGENOMIX Basic Information And Sales Area

Table 49: IGENOMIX. Products Portfolio

Table 50: Reproductive Genetic Innovations Basic Information And Sales Area

Table 51: Reproductive Genetic Innovations. Products Portfolio

Table 52: CombiMatrix Basic Information And Sales Area

Table 53: CombiMatrix. Products Portfolio

Table 54: Global Market Value (USD Million) (2025-2032) By Type

Table 55: Global Market Share (%) By Type (2032)

Table 56: Global Market Value (USD Million) (2025-2032) By Application

Table 57: Global Market Share (%) By Application (2032)

Table 58: Global Pre-Implantation Genetic Diagnosis (PGD) Market Value (USD Million) By Region

Table 59: Global Pre-Implantation Genetic Diagnosis (PGD) Market Share (%) By Region (2025-2032)

Table 60: North America Market Value (USD Million) (2025-2032) By Country

Table 61: North America Market Value (USD Million) (2025-2032) By Type

Table 62: North America Market Value (USD Million) (2025-2032) By Application

Table 63: Europe Market Value (USD Million) (2025-2032) By Country

Table 64: Europe Market Value (USD Million) (2025-2032) By Type

Table 65: Europe Market Value (USD Million) (2025-2032) By Application

Table 66: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 67: Asia Pacific Market Value (USD Million) (2025-2032) By Type

Table 68: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 69: South America Market Value (USD Million) (2025-2032) By Country

Table 70: South America Market Value (USD Million) (2025-2032) By Type

Table 71: South America Market Value (USD Million) (2025-2032) By Application

Table 72: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 73: Middle East & Africa Market Value (USD Million) (2025-2032) By Type

Table 74: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 75: Research Programs/Design For This Report

Table 76: Key Data Information From Secondary Sources

Table 77: Key Data Information From Primary Sources

Contact for Full Report

Loading report content...

Pre-Implantation Genetic Diagnosis (PGD) Market Overview

Loading chart…

Report Overview

Report Attribute	Details
Market size value in 2025	104.60 million
Revenue forecast in 2033	144.26 million
Growth rate	CAGR of 4.1% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Type, Application
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Roche; Genea Limited; Quest Diagnostics; Illumina, Inc.; Natera, Inc.; Cooper Medical, Inc.; LabCorp; California Pacific Medical Center (CPMC); Thermo Fisher Scientific Inc.; IGENOMIX; Reproductive Genetic Innovations; CombiMatrix
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

Growth Drivers2 items

Restraints2 items

Opportunities2 items

Challenges2 items

Market Segmentation

Loading chart…

Pre-Implantation Genetic Diagnosis (PGD) Segmentation Breakdown13 items

Type

Chromosomal Abnormalities

X-linked Diseases

Freeze Embryo Testing

Aneuploidy Screening

HLA

Others

Application

Stem Cell Therapy

IVF Prognosis

Late-Onset Genetic Disorders

Inherited Genetic Disease

Others

Regional Insights

Loading chart…

Competitive Landscape

Roche: Innovation pipeline in next-generation sequencing platforms

Illumina: OEM tie-ups for lab automation solutions

Natera: Service model specializing in non-invasive prenatal testing

LabCorp: Regional expansion across North American fertility clinics

Thermo Fisher: Vertical integration of reagent and instrumentation ecosystems

IGENOMIX: Technology partnerships for AI-based embryo selection tools

Key Pre-Implantation Genetic Diagnosis (PGD) Companies12 items

Roche

Genea Limited

Quest Diagnostics

Illumina, Inc.

Natera, Inc.

Cooper Medical, Inc.

LabCorp

California Pacific Medical Center (CPMC)

Thermo Fisher Scientific Inc.

IGENOMIX

Reproductive Genetic Innovations

CombiMatrix

Market Ecosystem

Diagnostic testing laboratories — perform PGD procedures using specialized equipment and reagents

Biotechnology firms — develop genetic analysis kits, sequencing platforms, and automation tools

Clinical service providers — integrate PGD into in vitro fertilization (IVF) protocols

Healthcare institutions — refer patients and manage clinical decision-making workflows

Regulatory agencies — establish standards for PGD validation and clinical adoption

Data analytics firms — process genomic datasets for diagnostic accuracy and reporting

Patient advocacy groups — influence demand through education and policy engagement

Recent Industry Insights

Analyst Overview

Table of Contents